Mapi - Pharma (Mapi - Pharma) Days Sales Outstanding : 0.00 (As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Days Sales Outstanding?

Mapi - Pharma's average Accounts Receivable for the six months ended in Jun. 2015 was $0.00 Mil. Mapi - Pharma's Revenue for the six months ended in Jun. 2015 was $0.00 Mil.

The historical rank and industry rank for Mapi - Pharma's Days Sales Outstanding or its related term are showing as below:

MAPI's Days Sales Outstanding is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 71.41
* Ranked among companies with meaningful Days Sales Outstanding only.

Mapi - Pharma's Days Sales Outstanding stayed the same from Jun. 2014 (0.00) to Jun. 2015 (0.00).

Mapi - Pharma Days Sales Outstanding Historical Data

The historical data trend for Mapi - Pharma's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Days Sales Outstanding Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Days Sales Outstanding

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
Days Sales Outstanding	-	-	-	-	-

Competitive Comparison of Mapi - Pharma's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mapi - Pharma's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's Days Sales Outstanding falls into.

Mapi - Pharma Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Mapi - Pharma's Days Sales Outstanding for the fiscal year that ended in Dec. 2014 is calculated as

	Days Sales Outstanding (A: Dec. 2014 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2013 )	+	Accounts Receivable (A: Dec. 2014 ))	/	count )	/	Revenue (A: Dec. 2014 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Mapi - Pharma's Days Sales Outstanding for the quarter that ended in Jun. 2015 is calculated as:

	Days Sales Outstanding (Q: Jun. 2015 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2014 )	+	Accounts Receivable (A: Jun. 2015 ))	/	count )	/	Revenue (A: Jun. 2015 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 2
=	0					/	0	*	365 / 2
=	N/A

Mapi - Pharma (NAS:MAPI) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Mapi - Pharma Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.